I listened to Graham Cooper, Geron's new CFO and there was nothing new. Results from four phase two trials at the end of this year and results from two phase two GRN 1005 trials in 2Q 2013. They have money for 2 years. If the trials have good results, we'll be in the money, big time. If the trials have poor results, we'll be broke, out of business. Geron up to $1.66 which is good, volume is low. It's wait and see.
ACTC is up on the news of third Dry AMD patient treated in Clinical Trial. Chief Scientific Officer Robert Lanza MD stated, "We are extremely pleased with the progress being made in all three of our clinical trials here in the US and the UK.
Good luck in this rigged casino,
No comments:
Post a Comment